TSAAI 2022 Annual Meeting

August 12, 2022 to August 14, 2022

It is an exciting time in the field of allergy and immunology!  This CME program is designed to allow attendees to continue exploring the Immunology Frontier.  Covered topics include Asthma, Antibody Deficiencies, Using Biologics, COVID Vaccines, Chronic Cough, Dematology and Hymenoptera Hypersensistivity.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma and Immunology.  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Commercial Support
This activity is supported in part by a medical education grant from CSL Behring and Takeda.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Discuss steps/approaches to align the effects individual biologics with characteristics and needs of specific asthma patients
  2. Recognize the clinical presentation of aspirin-exacerbated respiratory disease and distinguish it from aspirin-tolerant asthma
  3. Demonstrate competence in allergen selection and administration in successful cluster and rush subcutaneous immunotherapy (SCIT) regimens
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers


The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated


Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
Course expires: 
Event starts: 
08/12/2022 - 3:00pm CDT
Event ends: 
08/14/2022 - 11:30am CDT
William Busse MD
Disclosures: Consultant: AstraZeneca, Novartis, Regeneron, Sanofi, GlaxoSmithKline, Genentech
Katherine Cahill, MD
Disclosures: Advisory Board Member: Novartis, Regeneron, Sanofi, Genentech
                      Consultant: Blueprint Medicines, Ribon Therapeutics 
Monica Lawrence, MD
Disclosures: Other/Principal Investigator: American Lung Association, Jeffrey Modell Foundation, AAAAI 
                       Consultant: X4 Pharmaceuticals, Horizon Therapeutics
                       Other/Loan repayment program participant: NIH 
Jay Lieberman, MD
Disclosures: Advisory Board Member: DBV Technologies, Novartis
                      Speaker: Novartis/Genentech
                      Other/Data Safety Monitoring Committee Board Member: Siolta Therapeutics
                      Other/Research: Aimmune Therapeutics, DBV Technologies, Regeneron, Novartis
                      Other/Editorial Board Member: Annals of Allergy, Asthma and Immunology
                      Other/Committee Member: JTFPP, ABAI Board, ACAAI Food Allergy Committee Chair
Marc Serota, MD
Disclosures: Consultant: Regeneron, Sanofi-Genzyme, Genentech, Novartis, Pfizer, Celgene, Amgen
Mike Tankersley, MD
Disclosures: Consultant: ALK
                       Advisory Board Member: ALK
The following have no relevant financial relationships to disclose:
Karthik Krishnan, MD
Michelle Kittle, Meeting Coordinator

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.